Zusammenfassung
Der Morbus Bowen ist ein facettenreicher Tumor, der sich in
Abhängigkeit von der Lokalisation seines Auftretens in sehr
unterschiedlichen klinischen Bildern manifestiert. Die Polymorphie der Befunde
macht es notwendig, den Morbus Bowen von zahlreichen Differenzialdiagnosen
abzugrenzen, wobei primär entzündliche und infektiöse Dermatosen
sowie andere kutane Neoplasien zu berücksichtigen sind. Die Vielzahl der
klinischen Differenzialdiagnosen erklärt die Beobachtung, dass der Morbus
Bowen in der Regel erst nach Jahren diagnostiziert wird, und unterstreicht
gleichzeitig die Bedeutung der histopathologischen Untersuchung, die den
Schlüssel zur Diagnose des Morbus Bowen darstellt. In der folgenden
Übersicht werden schwerpunktmäßig die klinisch-morphologischen
Varianten des Morbus Bowen, seine typischen Differenzialdiagnosen und die
verschiedenen Therapieverfahren vorgestellt. Die Erythroplasie Queyrat, der
Morbus Bowen der Schleimhäute, wird aufgrund der klinischen Befunde und
des biologischen Verhaltens als eine Sonderform der Erkrankung verstanden und
ist daher in der vorliegenden Publikation nicht berücksichtigt worden.
Abstract
Bowen's disease is a multivarious tumor, which manifests itself
as a function of the localization of its occurrence in very different clinical
pictures. The polymorphism of the findings makes it necessary to distinguish
Bowen's disease from numerous differential diagnoses whereby primarily
inflammatory and infectious dermatoses as well as other cutaneous neoplasias
are to be considered. The multiplicity of the clinical differential diagnoses
explains on one hand the observation that Bowen's disease is usually only
diagnosed after years and on the other hand underlines the importance of the
histological investigation, which represents the key to the diagnosis of
Bowen's disease. In the following review the clinical and morphological
variants of Bowen's disease, its typical differential diagnoses and the
different therapeutic options are presented. The Erythroplasia of Queyrat,
Bowen's disease of the mucous membranes, is understood due to the clinical
findings and the biological behavior as a special form of the disease and
therefore not considered herein.
Literatur
- 1 Braun-Falco O, Plewig G, Wolff H H. Dermatologie und Venerologie 4. Aufl. Berlin;
Springer 2002
- 2 Hoede N.
Morbus Bowen. In: Korting GW (Hrsg). Dermatologie in Praxis und Klinik. Stuttgart; Thieme 1981
- 3
Kao G F.
Carcinoma arising in Bowen's disease.
Arch Dermatol.
1986;
122
1124-1126
- 4
Kreysel H W, Schulte-Hermann N.
Die Tumoren der Haut.
Med Welt.
1977;
18
233-243
- 5 Stadler R, Hartig C.
Epidermale Tumoren. In: Kerl H, Garbe C, Cerroni L, Wolff HH (Hrsg). Histopathologie der Haut. Berlin;
Springer 2003
- 6
Jaeger A N, Gramkow A, Hjalgrim H. et al .
Bowen disease and risk of subsequent malignant
neoplasms.
Arch Dermatol.
1999;
135
790-793
- 7
Kossard S t, Rosen R.
Cutaneous Bowen's disease.
J Am Acad Dermatol.
1992;
27
406-410
- 8
Andersen S LC, Nielsen A, Reymann F.
Relationship between Bowen's disease and internal
malignant tumors.
Arch Dermatol.
1973;
108
367-370
- 9
Thestrup-Pedersen K, Ravnborg L, Reymann F.
Morbus Bowen: a description of the disease in 617
patients.
Acta Derm Venereol.
1988;
68
236-239
- 10
Lee M M, Wick M M.
Bowen's disease.
CA Cancer J Clin.
1990;
40
237-242
- 11
Bell H K, Rhodes L E.
Bowen's disease – a retrospective review of
clinical management.
Clin Exp Dermatol.
1999;
24
338-339
- 12 Hundeiker M.
Krankheiten durch Arsen oder Arsenverbindungen. In: Kühl M, Klaschka F (Hrsg). Berufsdermatosen. München; Urban u. Schwarzenberg
1990
- 13
Denk R H, Holtzmann H, Lange H J. et al .
Über Arsenspätschäden bei obduzierten
Moselwinzern.
Med Welt.
1968;
75
760-762
- 14 Meier F, Breuninger H.
Morbus Bowen mit Bowen-Karzinom im Bereich der
Zehenzwischenräume nach langjähriger antimykotischer Therapie mit
formaldehydhaltigen Externa. In: Tilgen W, Petzoldt D (Hrsg). Operative und konservative Dermato-Onkologie. Berlin;
Springer 1995
- 15 Reichenberger M, Richter M.
Das Pechhautleiden, insbesondere Verlauf und Prognose der
Kanzerosen bzw. Präkanzerosen. In: Petres J, Müller R (Hrsg). Präkanzerosen und Papillomatosen der Haut. Berlin;
Springer 1981
- 16
Melnikova V O, Ananthaswamy H N.
Cellular and molecular events leading to the development of
skin cancer.
Mutation Res.
2005;
571
91-106
- 17
Baran R L, Gormley D E.
Polydactylous Bowen's disease of the nail.
J Am Acad Dermatol.
1987;
17
201-204
- 18
Cox N H, Eedy D J, Morton C A.
Guidelines for management of Bowen's disease.
Br J Dermatol.
1999;
141
633-641
- 19
Goodman G, Mason G, O'Brien T.
Polydactylous Bowen's disease of the nail bed.
Australas J Dermatol.
1995;
36
164-165
- 20
Ongenae K, van de Kerckhove M, Naeyaert J M.
Bowen's disease of the nail.
Dermatology.
2002;
204
348-350
- 21
Ragi G, Turner M S, Klein L E. et al .
Pigmented Bowen's disease and review of 420 Bowen's
disease lesions.
J Dermatol Surg Oncol.
1988;
14
765-769
- 22 Hundeiker M.
Krankheiten durch ionisierende Strahlen. In: Kühl M, Klaschka F (Hrsg). Berufsdermatosen. München; Urban u. Schwarzenberg
1990
- 23 Hundeiker M.
Präkanzerosen und Pseudokanzerosen. In: Korting GW (Hrsg). Dermatologie in Praxis und Klinik. Stuttgart; Thieme 1981
- 24
Goldschmidt H.
Dermatologische Röntgentherapie und
Radiokarzinogenese.
Hautarzt.
1982;
33
183-190
- 25
Clavel C E, Pham Huu V, Durlach A P. et al .
Mucosal oncogenic human papillomaviruses and extragenital
Bowen disease.
Cancer.
1999;
86
282-287
- 26
Mitsuishi T, Sata T, Matsukura T. et al .
The presence of mucosal human papillomavirus in Bowen's
disease of the hands.
Cancer.
1997;
79
1911-1917
- 27
Pfister H, ter Schegget J.
Role of HPV in cutaneous premalignant and malignant
tumors.
Clin Dermatol.
1997;
15
335-347
- 28
Parker S G, Diffey B L.
The transmission of optical radiation through human
nails.
Br J Dermatol.
1983;
108
11-16
- 29
Ahmed I, Berth-Jones J, Charles-Holmes S. et al .
Comparison of cryotherapy with curettage in the treatment of
Bowen's disease: a prospective study.
Br J Dermatol.
2000;
143
759-766
- 30
Cox N H.
Body site distribution of Bowen's disease.
Br J Dermatol.
1994;
130
714-716
- 31
Eedy D J, Gavin A T.
Thirteen-year retrospective study of Bowen's disease in
Northern Ireland.
Br J Dermatol.
1987;
117
715-720
- 32
Leibovitch I, Huilgol S C, Selva D. et al .
Cutaneous squamous carcinoma in situ (Bowen's disease):
treatment with Mohs micrographic surgery.
J Am Acad Dermatol.
2005;
52
997-1002
- 33
Baran R, Simon C.
Longitudinal melanonchyia: a symptom of Bowen's
disease.
J Am Acad Dermatol.
1988;
18
1359-1360
- 34
Baran R, Eichmann A.
Longitudinal melanonychia associated with Bowen's
disease: two new cases.
Dermatology.
1993;
186
159-160
- 35
Lambiase M C, Gardner T L, Altman C E. et al .
Bowen disease of the nail bed presenting as longitudinal
melanonychia: detection of human paillomavirus typ 56 DNA.
Cutis.
2003;
72
305-309
- 36
Saxena A, Kasper D A, Campanelli C D. et al .
Pigmented Bowen's disease clinically mimicking melanoma
of the nail.
Dermatol Surg.
2006;
32
1522-1525
- 37
Stante M, DeGeorgi V, Massi D. et al .
Pigmented Bowen's disease mimicking cutaneous melanoma:
clinical and dermascopic aspects.
Dermatol Surg.
2004;
30
541-544
- 38
Mirza B, Muir J B.
Bowen's disease of the nail bed.
Australas J Dermatol.
2004;
45
232-233
- 39
Wagner G, Gerfelmeyer G.
Pigmentiertes subunguales Fremdkörpergranulom.
Akt Dermatol.
1994;
20
188-189
- 40
Baran R, Perrin C.
Bowen's disease clinically simulating an
onchyomatricoma.
J Am Acad Dermatol.
2002;
47
947-949
- 41
Kaiser J F, Proctor-Shipman L.
Squamous cell carcinoma in situ (Bowen's disease)
mimicking subungual verruca vulgaris.
J Fam Pract.
1994;
39
384-387
- 42
Kapranos N, Aronis E, Branziotis A. et al .
HPV-16-assoziierter Morbus Bowen des Nagelbetts und der
Periungual-Region beider Daumen.
H u G.
1996;
71
48-50
- 43
Mikhail G R.
Bowen's disease and squamous cell carcinoma of the nail
bed.
Arch Derm.
1974;
110
267-270
- 44
Weisenseel P, Prinz J, Korting H.
Therapie eines paraungualen HPV-73-positiven Morbus Bowen mit
Imiquimod-Creme.
Hautarzt.
2006;
57
309-312
- 45
Kopke L FF, Konz B.
Mikrographische Chirurgie.
Hautarzt.
1995;
46
607-614
- 46
Kunte C, Konz B.
Aktuelle Therapieempfehlungen für das Basalzellkarzinom
und Plattenepithelkarzinom der Haut.
Hautarzt.
2007;
58
419-426
- 47
Graham J H, Helwig E B.
Bowen's disease and its relationsship to systemic
cancer.
Arch Dermatol.
1961;
83
76-96
- 48
Veien S K, Veien N K, Hattel . et al .
Results of treatment of non-melanoma skin cancer in a
dermatologic practice. A prospective study.
Ugeskrift Laeger.
1996;
158
7213-7215
- 49
Breibart E W.
Kryochirurgie: Methodik und Ergebnisse.
Hautarzt.
1983;
34
612-619
- 50
Sebastian G, Stein A.
Kryotherapie epithelialer Tumoren.
H u G.
1997;
72
92-97
- 51
Scholz A, Sebastian G.
10-Jahres-Bericht zur Kryotherapie in der Dermatologie.
Z Klin Med.
1988;
43
271-274
- 52
Morton C, Horn M, Leman J. et al .
Comparison of topical methyl aminolevulinate photodynamic
therapy with cryotherapy or Fluorouracil for treatment of squamous cell
carcinoma in situ: results of a multicenter randomized trial.
Arch Dermatol.
2006;
142
729-235
- 53
Tantikun N.
Treatment of Bowen's disease of the digit with carbon
dioxide laser.
J Am Acad Dermatol.
2000;
43
1080-1083
- 54
Gordon K B, Garden J M, Robinson J K.
Bowen's disease of the distal digit. Outcome of
treatment with carbon dioxide laser vaporization.
Dermatol Surg.
1996;
22
723-728
- 55
Vaisse V, Clerici T, Fusade T.
Bowen disease treated with scanned pulsed high energy
CO2 laser. Follow-up of 6 cases.
Ann Dermatol Venereol.
2001;
128
1220-1224
- 56 Braun-Falco O, Lukacs S. Dermatologische Röntgentherapie. 1. Aufl Berlin; Springer
1973
- 57
VanderSpek L A, Pond G R, Wells W. et al .
Radiation therapy for Bowen's disease of the skin.
Int J Radiat Oncol Biol Phys.
2005;
63
505-510
- 58
Dupree M T, Kiteley R A, Weismantle K. et al .
Radiation therapy for Bowen's disease: lessons for
lesions of the lower extremity.
J Am Acad Dermatol.
2001;
45
401-404
- 59
Salim A, Leman J A, McColl J H. et al .
Randomized comparison of photodynamic therapy with topical
5-fluorouracil in Bowen's disease.
Br J Dermatol.
2003;
148
539-543
- 60
Tan B, Sinclair R, Foley P.
Photodynamic therapy for subungual Bowen's disease.
Australas J Dermatol.
2004;
45
172-174
- 61
Usmani N, Stables G I, Telfer N R. et al .
Subungual Bowen's disease treated by topical
aminolevulinic acid-photodynamic therapy.
J Am Acad Dermatol.
2005;
53
S 273-276
- 62
Sturm H M.
Bowen's disease and 5-fluorouracil.
J Am Acad Dermatol.
1979;
1
513-522
- 63
Fulton J E, Carter D M, Hurley H J.
Treatment of Bowen's disease with topical 5-fluorouracil
under occlusion.
Arch Dermatol.
1968;
97
178-180
- 64
Bargman H, Hochman J.
Topical treatment of Bowen's disease with
5-Fluorouracil.
J Cutan Med Surg.
2003;
7
101-105
- 65
Mackenzie-Wood A, Kossard S, de Launey J. et al .
Imiquimod 5 % cream in the treatment of
Bowen's disease.
J Am Acad Dermatol.
2001;
44
462-470
- 66
Patel G K, Goodwin R, Chawla M. et al .
Imiquimod 5 % cream monotherapy for cutaneous
squamous cell carinoma in situ (Bowen's disease): a randomized,
double-blind, placebo-controlled trial.
J Am Acad Dermatol.
2006;
54
1025-1032
- 67
Rosen T, Harting M, Gibson M.
Treatment of Bowen's disease with topical
5 % imiquimod cream: retrospective study.
Dermatol Surg.
2007;
30
427-432
Dr. Gunnar Wagner
Klinikum Bremerhaven Reinkenheide
Postbrookstraße 103
27574 Bremerhaven
